Business, Drugs and Pharmaceuticals, Free News Articles

Oral Vaccine Boosts COVID Immunity: study conducted on nonhuman primates is published in the journal Vaccine

ROCHESTER, Minn. -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced results confirming the activity of an oral vaccine formulation for boosting immunity against SARS-CoV-2. The full study conducted on nonhuman primates is published in the journal Vaccine accessible at http: https://www.sciencedirect.com/science/article/pii/S0264410X21016716

The article describes the evaluation of an oral COVID-19 vaccine built on the vesicular stomatitis virus (VSV) platform. Oral administration of the VSV based vaccine induced antibodies that could neutralize SARS-CoV-2, the virus that causes COVID-19. More importantly, the novel oral formulation powerfully boosted the levels of neutralizing antibodies against SARS-COV-2 in previously vaccinated monkeys. The oral vaccine was shown to be safe and did not cause clinically significant adverse effects.

"By tweaking the way we generate the VSV-SARS vaccine, we created a new oral formulation that worked remarkably well to boost virus neutralizing antibody titers when administered into the cheek pouches of cynomolgus macaques whose immunity was waning after they had been primed with an intramuscular vaccine," stated Kah-Whye Peng, Ph.D., Chief Technical Officer of Vyriad, and first author of this publication. "Oral dosing is convenient and more likely to be accepted by people who are reluctant to receive yet another intramuscular injection to boost their immunity."

The COVID-19 pandemic is not over and there is a continued need to deliver vaccines to a much of the world's population. An effective oral vaccine/booster has the potential to dramatically improve vaccine uptake rates by addressing some of the key barriers to effective deployment such as logistics of distribution to remote populations, fear of needles, and administration to young children.

"We are excited by these groundbreaking findings. Vyriad has cGMP manufacturing capabilities and is running clinical trials using an engineered VSV for cancer therapy. We are therefore actively seeking partnership to help bring this promising platform to human testing," stated Stephen J Russell, M.D., Ph.D., Chief Executive Officer of Vyriad.

The publication is a collaboration between researchers at Vyriad, Imanis Life Sciences, Regeneron Pharmaceuticals, and the University of Minnesota.

About Vyriad, Inc.

Vyriad is a clinical-stage company developing virus-based therapeutics, focusing initially on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad is working with VSV, measles and picornavirus platforms, programming their viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platform, derived from vesicular stomatitis virus (VSV), is being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have a well-established broad-based strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad's VSV platform and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab-rwic) as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

For more information, visit https://vyriad.com/.

Related link: https://vyriad.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles

Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies

OKLAHOMA CITY, Okla. -- Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC's proprietary offering of MHC peptide targets for oncology with Myrio's revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based on targets distinct to tumors across multiple types of cancer.

The cancer therapies resulting from this collaboration will represent a unique synergism: Myrio's ReD platform is differentiated in its ability to routinely identify antibodies that bind to peptides from intracellular proteins presented on the cell surface by major histocompatibility complex (MHC), and Pure MHC is a world-leader in the identification and validation of peptide/MHC (pMHC) targets. Antibodies to next generation pMHC oncology targets may provide more efficacious therapies, particularly for solid tumors, while minimizing off-target effects for patients.

Researchers at both companies expressed excitement at the prospect of combining these innovative approaches:

"The speed and flexibility of Myrio's ReD platform enables the generation of robust antibody-based therapies against challenging targets like pMHC with high affinity and specificity," said Myrio's CEO Pete Smith. "Pure MHC's curated pMHC targets are an excellent fit for our platform and substantially de-risk downstream development."

Pure MHC's Chief Scientist, William Hildebrand, PhD shared this enthusiasm, "Pure MHC is dedicated to the identification of pMHC complexes distinct to cancer and absent from healthy tissues. Peptide/MHC complexes for several oncology indications have been identified by Pure MHC as present on tumors yet absent from healthy tissue, and we are excited for Myrio to deploy their cutting-edge technology to engineer antibodies that recognize our targets with great specificity."

From a business perspective, these therapeutic candidates will bolster Myrio's existing portfolio of in-house assets while providing Pure MHC access to a powerful antibody platform that enables multiple therapeutic pipelines.

"Myrio's platform is not just an outstanding scientific fit, the collaboration represents a unique and exciting way for Pure MHC to deploy its novel target assets strategically," said Kris Looney, President of Pure MHC. "As we continue to provide targets from our pipeline to the market via more traditional partner licensing models, we felt the time was right to also establish our own therapeutic pipeline and have found exactly the collaborator we need in Myrio."

Pete Smith agreed, "With the close alignment of both scientific and business objectives between our two companies, a partnership between Myrio and Pure MHC just makes so much sense. We are excited about its potential."

The companies expect the collaboration to yield therapeutic candidates within the next twelve months.

About Myrio Therapeutics

Myrio Therapeutics is driving a new frontier of antibody-based therapies as the company's Retained Display(tm) (ReD) antibody platform offers identification of highly specific human antibodies that bind to peptide-MHC complexes. Myrio's antibodies can readily be converted into multispecific, CAR-T or other formats, dramatically increasing the target landscape for these modalities. Visit: http://www.myriotx.com/

About Pure MHC

Pure MHC, LLC is a platform technology company funded and managed by Emergent Technologies, Inc. with expertise in disease-specific target identification and validation as well as immunotherapeutic drug development for cancer, infectious disease, and autoimmune diseases. The Pure MHC target discovery technology was developed by Chief Scientist William Hildebrand, Ph.D., of the University of Oklahoma Health Science Center. For more information, visit: https://puremhc.com/

About Emergent Technologies

Emergent Technologies, Inc. is an innovation solutions and technology commercialization leader headquartered in Austin, Texas. Visit: http://www.etibio.com/

Related link: https://puremhc.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, Funding and Investment

Neurosoft Bioelectronics Receives Nearly $3 Million in Funding

NEW YORK, N.Y. -- Neurosoft Bioelectronics, an early-stage company developing tools for unmet needs in epilepsy and tinnitus, was awarded nearly $3 million USD, from the SERI-Funded European Innovation Council Accelerator Grant and a share of the $165,000 USD through the European Research Council Proof-of-Concept Grant. Additionally, the firm secured a $100,000 convertible note from the Fongit Innovation Fund.

Proceeds will fund continued development of the company's soft flexible electrodes to be marketed as SOFT ECoG™, a family of implantable devices which can seamlessly interface with the brain. The novel devices are up to 1000x softer and 2x thinner than clinical electrodes, with integrated electrode sites up to 100x smaller, making them suited for high-resolution recording and stimulation of the brain for up to thirty days. Their conformability and softness make them ideally suited for placement in the sulci of the brain - hard to reach areas of the brain where many disorders may best be treated. The deep folds of a sulcus are inaccessible for other electrodes while SOFT ECoG can be safely and precisely placed for stimulation and recording.

"Given that 70% of the surface of the brain is buried in sulci, it was critical to develop a technology that could safely and effectively work in those spaces," said Neurosoft Bioelectronics' CEO, Nicolas Vachicouras, Ph.D. "We're eager to put these significant funds toward clinical testing and regulatory approval of SOFT ECoG in the upcoming months, which will simultaneously drive progress of SOFT TINNIT. Together, these products have the potential to bring relief to epilepsy, brain tumor, and tinnitus patients, and in the future will impact those living with other neurological disorders such as deafness, blindness, tetraplegia, and chronic pain."

Vachicouras will present an update about the company and technology at the Bioelectronic Medicine Forum in New York today.

Most of the funds are designated for the further development of SOFT ECoG however, the innovations made will simultaneously advance the company's second product, SOFT TINNIT™. SOFT TINNIT is a chronic implant to perform closed-loop neuromodulation of the cortex to provide relief for patients suffering from severe tinnitus. Severe tinnitus, which has no cure, affects more than 7 million people in the U.S. and Europe.

Learn more: https://www.neurosoft-bio.com/technology

About Neurosoft Bioelectronics

Neurosoft Bioelectronics Ltd. is a Swiss medtech spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL). Neurosoft Bioelectronics develops next generation soft implantable electrodes to interface with the brain for the treatment of severe neurological disorders. Its main product is a fully implantable closed-loop Brain-Computer Interface (BCI) to treat severe tinnitus, a condition that affects 7M people in the US and Europe, of which 7% attempt suicide every year. It is also developing a family of subdural electrodes intended for monitoring during brain tumor and epilepsy resection surgery.

Learn more at: https://www.neurosoft-bio.com/

RELATED LINKS:

https://neurotechreports.com/pages/bioelectronic-medicine-forum.html

Related link: https://www.neurosoft-bio.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC and Vall d’Hebron University Hospital Announce Research Collaboration

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with Vall d'Hebron Barcelona Hospital Campus to develop new technologies for B-cell monitoring in transplant rejection.

The research is being led by Drs. Oriol Bestard and Rico Buchli and focuses on the detection of alloreactive memory B cells for pre-transplant risk stratification and post-transplant monitoring. Recognition of non-self HLA gives rise to the formation of HLA-specific memory B cells which precede circulating HLA antibodies. Importantly, such HLA-specific memory B cells can be present even in the absence of detectable serum antibodies, being an additional rejection risk factor in transplantation. Memory B cells are responsible for immunological recall responses by differentiating into antigen-specific antibody-producing cells upon re-encounter with a miss-matched antigen.

"This collaboration with PTS validates the tremendous need for appropriate and routinely applicable assays to detect and visualize the presence and HLA specificity of alloreactive memory B cells in solid organ transplant patients, which may ultimately help improve current alloimmune-risk stratification," Dr. Bestard stated.

"Today, the immunological risk of an individual transplant patient is mainly assessed by detection of HLA antibodies in the serum, which are produced by long lived bone marrow-residing plasma cells. At PTS, we envision that in addition to serum HLA antibody detection, HLA-specific memory B cell assays will serve as supplemental tools to determine risk factors and help improve individual patient management," said Dr. Buchli.

Steve Mayer MD, Chief Medical Officer at PTS stated, "We're very excited about the potential of this technology because it allows a very early diagnostic view of an individual's risk of rejection before any graft damage has occurred. Also, the technology is likely to have a significant impact on clinical utility with high predictive values."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: https://www.puretransplant.com/.

About Pure Protein, LLC

Pure Protein, L.L.C. is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its ecommerce website, https://www.hlaprotein.com/, Pure Protein offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Vall d'Hebron Barcelona Hospital Campus

We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management. The Vall d'Hebron Barcelona Hospital Campus is the combination of our five entities: the Vall d'Hebron University Hospital, the Vall d'Hebron Research Institute (VHIR), the Vall d'Hebron Oncology Institute (VHIO), the Multiple Sclerosis Center of Catalonia (CEMCAT) and the Autonomous University of Barcelona.

We are constantly in touch with patients; our starting point is the challenges they present in our day-to-day work to continue to innovate and find new diagnostic methods and treatments. The talented team that has made us a leading institution allows us to work towards attracting excellence and training the best professionals in clinical practice.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Free News Articles, NonProfit and Charities, Regional Events

November Is C. difficile Awareness Month With An Annual Conference, Recognizing Subject Matter Experts, Expressing Gratitude to US Governors

TAMPA, Fla. -- C Diff Foundation announced today that the 9th Annual International C. diff. Conference and Health EXPO welcomed over 40 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, and academia on November 4-5, 2021. World-renowned presenters delivered data and discussed critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues: 100% Live-online presentations.

The Conference registration was complimentary this year. To learn more about this extraordinary conference, guest speakers, and the diverse topics presented visit: https://www.cdiff2021.com

For conference coverage visit ContagionLive Infectious Diseases Today: https://www.contagionlive.com/latest-conference

On behalf of the C Diff Foundation, Sahil Khanna, M.B.B.S, M.S. proudly presented the Lifetime Achievement Award to Dale Gerding, MD, MACP, FIDSA, FSHEA for his outstanding vision, dedication, and commitment and for the advancement of Clostridioides difficile research, development, and care through the years. The Dale Gerding Lifetime Achievement award will be presented annually during the C Diff Foundation's November conference to a healthcare professional meeting the criteria, nominated by peers, and awarded by Dr. Gerding himself.

The C Diff Foundation "Making a Difference: Innovations in Infection Prevention" 2021 award was presented to PhoneSoap acknowledging their exceptional organization who is making a difference in the Infection Prevention community, with their innovative products, services, and technologies.

The award was accepted by Wes LaPorte, CEO of PhoneSoap. "PhoneSoap's mission has always been to limit the spread of infectious diseases through science and technology. We are honored to accept the Innovations in Infection Prevention award of 2021 from the C Diff Foundation given their very important endeavor to bring awareness, education, and advocacy globally," stated LaPorte.

According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care- associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine).

Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and has a mortality rate of approximately 9.3%.

The C Diff Foundation expresses their gratitude to all the Sponsors and Keynote speakers for their generous support of the 9th Annual International C. diff. Conference and Health EXPO. Together we deliver superior educational up-to-date data, advance the healthcare professional knowledge and understanding of the topics discussed, and serve as the leading organization educating and advocating for C. difficile infection prevention, treatments, clinical trial, diagnostics, support, and environmental safety worldwide. We are grateful to be the leading resource for patients, families, caregivers, and healthcare professionals.

Many US Governors have signed a state proclamation proclaiming November 2021 as Clostridioides difficile (C. difficile, C. diff.) Infection Awareness Month.

"Our shared goal is to witness a significant increase in C. difficile awareness, with a noted reduction in C. difficile infections worldwide by the year 2025. We would also like to thank Seres Therapeutics, Rebiotix, a Ferring Company, and Ferring Pharmaceuticals for their efforts and support with this endeavor," stated Nancy C. Caralla, Executive Director of the C Diff Foundation.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient, caregiver, and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide.

For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiff2021 #cdiffawarenessmonth

C Diff Foundation(TM) is a trademark of C Diff Foundation, established 2012 in the U.S.

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Kalyagen™ Announces Registration of STEMREGEN® in Spain, CEO at Madrid Stem Cell Symposium

AUSTIN, Texas -- Kalyagen is pleased to announce the successful product registration of STEMREGEN® in Spain. This announcement coincides with Christian Drapeau's, CEO and Chief Scientist of Kalyagen, trip to Madrid, Spain last week to speak at the IV Jornadas Internacionales Otto H. Warburg symposium at the NH Madrid Príncipe de Vergara.

Mr. Drapeau also visited Miguel Garber, MD, Vice Chairman of the Spanish Society of Regenerative Medicine and Cell Therapy regarding the ongoing multicenter clinical trial, "The Effect of Stemregen and Adipose Stroma Vascular Fraction (SVF) Either Individually or in Combination in Patient With Heart Failure," to evaluate the use of stem cell therapies in patients suffering from heart failure. STEMREGEN® is a natural stem cell enhancer documented to increase the number of circulating stem cells by stimulating Endogenous Stem Cell Mobilization (ESCM). Dr. Garber will be the primary contact in Europe for STEMREGEN®.

"We are delighted that we will now be able to offer STEMREGEN to the people of Spain. The link between a lower number of circulating stem cells and the development of age-related diseases has been well studied with numerous degenerative conditions, including diabetes, cardiovascular diseases, atherosclerosis, Alzheimer's disease, rheumatoid arthritis, pulmonary diseases, erectile dysfunction, and kidney disease," said Christian Drapeau. "From a therapeutic standpoint, increasing the number of circulating stem cells has been documented to enhance tissue repair or improve the course of disease formation in cases of acute myocardial infarction and many other degenerative conditions."

The trial, whose first phase is expected to be completed in the spring of 2022, aims to evaluate the effect of ESCM in cases of heart failure. Study participants will be evaluated over several months, at which times their NYHA functional classification and echocardiographic parameters will be assessed.

STEMREGEN® is a unique and patent-pending blend of proprietary plant-based extracts documented to support ESCM. Ingredients in STEMREGEN® have been investigated in more than eight studies for their effect on stem cell function, of which five were randomized, double- blind, placebo-controlled human clinical trials. STEMREGEN® has wide application in antiaging and overall health maintenance.

More information about the clinical trial can be found at https://clinicaltrials.gov/ct2/show/NCT04515537.

About Kalyagen

Kalyagen™ was founded by Christian Drapeau, author of the bestseller Cracking the Stem Cell Code. Kalyagen is a leader in the research and development of natural products aimed at supporting stem cell function of the body. Stem cells constitute the natural repair system of the body, and stem cell enhancers have been documented to strongly contribute to improving health and quality of life. STEMREGEN® is the first stem cell enhancer product developed by Kalyagen™. STEMREGEN® is a unique blend of proprietary plant-based extracts documented to support Endogenous Stem Cell Mobilization and provide other health benefits. For more information, please visit our website: https://www.kalyagen.com/.

About Miguel Garber

Miguel Garber over 32 years experience in Internal medicine and cardiology, with expertise in regenerative medicine, training and education, research. He has more than 14 years working with Stem Cells, Therapeutics Department of American Medical Information Group and Clinica Quirurgica Quantum. Medical Director of Regenerative Medicine Madrid, Professor of Master in Regenerative Medicine and Scholarly Journals Editor. Vice-chairman - Sociedad Española de Medicina Regenerativa y Terapia Celular. Dr. Garber can be reached at mggarber@gmail.com.

CONTACT:

Biomics, LLC (dba Kalyagen™)

Herbert Dogan, Chief Marketing Officer (310-433-8072)

hgd@kalyagen.com

Social media: @kalyagen #stemthetideoftime #stemthetide

Disclaimer: None of the statements contained in this press release have been evaluated by the U.S. Food and Drug Administration. The products and information in the release are not intended to diagnose, treat, cure or prevent any disease.

Related link: https://www.kalyagen.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities

Gala to end Pancreatic Cancer Raises Over $1 Million

ATLANTA, Ga. -- Purple Pansies, a pancreatic cancer nonprofit organization, recently held its 12th annual Pillars of Hope Gala, presented by Kroger, raising more than $1 million in one evening. The gala was officially renamed Pillars of Hope by the nonprofit to show support for survivors and the hope to cure pancreatic cancer.

Founding Purple Pansies in 2008, Maria Fundora holds the gala in September in honor of when she lost her mother, Iluminada Milian, in 2007. "She fought so hard," Fundora said. "When I lost her three months after diagnosis I could not just sit still. I had to do something. I had to fight, to be able to find a way to help others, so others would not go through what my family went through."

The evening included a presentation of the inaugural Pillars of Hope Bill Palmer Legacy Award.

The award honors the late Bill Palmer (founder of Applebee's) for his pioneering support of Purple Pansies and his own courageous fight with the disease. For the first year of this award, Tim Brown, Atlanta President of Kroger, received the award for his involvement and service, both personally and professionally.

"Kroger and our partners are excited to be involved with Purple Pansies and Pillars of Hope and to be able to assist in raising money for this organization. I was truly honored to be recognized and receive the Bill Palmer Legacy Award," said Tim Brown, president of the Kroger Atlanta division. "My wife, Angie, and I look forward to supporting this organization in the future."

According to the American Cancer Society, research for pancreatic cancer is one of the least funded of all cancers. The organization is guided by "CARS": Community, awareness and resources.

To date, Purple Pansies has raised over $4 million to support research and clinical trials through the Phoenix-based Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

"We have learned people are coming in earlier to diagnose pancreatic cancer," said Dr. Daniel Von Hoff, Distinguished Professor in TGen's Molecular Medicine Division. "Stage 1a early pancreas cancer 5 year survival rates have grown from 45% to 84% due to awareness with events like this gala."

During the gala, a video featured Dr. Von Hoff, describing how pancreatic cancer treatments are improving and a current clinical trial of patients on a ketogenic diet. He encouraged the fight and displayed a purple bracelet made by Lana Stowell, a local Alpharetta, Ga., youth. Everyone in the audience received one of the more than 200 bracelets made by Lana to join us together as a community.

Dr. Andrew Page, M.D., director of surgical oncology and HPB surgery at Piedmont Healthcare, spoke about the unique fight of pancreatic patients: "They all share in common their trust in me which I treasure and their warrior spirit which I honor ... Let's keep going."

During the evening, Purple Pansies officially announced the launch of their scholarship program for high school seniors who have a parent, guardian or are themselves suffering from pancreatic cancer. Their goal is to continue support families across the country that have been affected by pancreatic cancer.

Additional information can be found at https://purplepansies.org/

FOLLOW ON SOCIAL AT:

https://www.facebook.com/pplpansies/

https://twitter.com/pplpansies

https://www.instagram.com/pplpansies/

Related link: https://purplepansies.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles

Drink HRW Hydrogen Tablets Improve Markers of Aging in the Elderly

COQUITIAM, B.C. -- Aging is a reality that we all deal with, with age-related diseases creating a massive burden on our healthcare system. In recent years, researchers have begun exploring therapeutics that could potentially stave off, or even reverse, some of the deterioration associated with aging. Now, Drink HRW reports that a new randomized, placebo controlled clinical trial that followed elderly participants for 6 months, published online October 1st in Experimental Gerontology, explains that high doses of hydrogen water (HRW), delivered via hydrogen tablets, could be an effective strategy at improving multiple age-related measurements and outcomes in an elderly population.

The randomized, placebo-controlled cross-over trial compared the effects of chronic administration of hydrogen-rich water, created by hydrogen tablets, against baseline conditions and placebo control for numerous markers associated with the aging process in an elderly population (70+). Participants consumed either HRW, or placebo water, for 6 months. HRW lengthened telomeres, whereas the placebo group saw a decrease, improved brain metabolism, lowered subjective reports of pain, improved parameters within the senior fitness test, and led to strong trends regarding improvements in DNA methylation, increased antioxidant activity, and reduced oxidative stress.

Shortening telomeres have been hypothesized as being a causative factor in the aging process. As telomeres shorten, incidence of disease and deterioration increases, and survival outcomes decrease. Additionally, a decline in brain metabolism has been linked to onset of many neurological issues.

Sergej Ostojic, M.D., PH.D., Professor of Medicine at the University of Novi Sad, a senior author of the Experimental Gerontology study said, "We have been investigating hydrogen use in medicine in my lab for over a decade, and we already recognized its potential to improve metabolic health and every-day functioning in elderly. However, this study for the first time demonstrated its potential to improve several molecular and phenotypic biomarkers of aging. It's perhaps too early to say that hydrogen is an anti-aging compound but this study opens a new chapter in hydrogen research and implementation, and emphasizes several pathways linked with hydrogen action in the human body."

Alex Tarnava, Chief Executive Officer of Drink HRW said, "The aging process leads to deterioration and disruption in many of the key functions within our bodies. Molecular hydrogen has shown across 2000 publications and 120+ human studies to play a corrective role in restoring many of these proper functions, such as improving metabolic markers, promoting a healthy inflammatory response, and supporting the delicate harmony between our bodies natural levels of antioxidants and beneficial oxidative stressors. This is an important study that demonstrates the potential or high-dose hydrogen therapy to slow down, or even temporarily reverse, some of the deterioration aging causes."

Tarnava added, "At Drink HRW we deliver the highest dosage and concentration of hydrogen in water instantly available anywhere in the world, and we are committed to supporting research around the world to better understand this important and fascinating molecule. We work with researchers to search for the truth, believing strongly that the researchers, not private companies, should have the sole authority to decide if they will publish results. We believe pursuit of the truth and integrity in research is the best path towards long term growth."

Sergej Ostojic is a senior biomedical scientist with a broad research background in medicine, applied physiology, and nutrition. He is a board-certified M.D. and holds a Ph.D in Medical Sciences. Dr. Ostojic currently works as a full professor of biomedical sciences at the University of Novi Sad, and an adjunct professor at the University of Belgrade School of Medicine. His research expertise and experience include pre-clinical and clinical development of mitochondria-related nutraceuticals and nutritional supplements, tissue-specific metabolic assessment and translation, and work physiology.

He has authored more than 200 scientific papers, 30 book chapters and books, and 5 patent applications, and has been the recipient of internationally competitive research scholarships including a WADA Scientific Research Grant, the NSCA International Award, research grants from the World Health Organization and European Commission, and many industrial endowments.

About Drink HRW

Drink HRW is on a mission to revolutionize the supplement industry with a new, science-based approach. In just 4 years of availability, various research teams have published 9 clinical trials and 4 case studies using their products, with an additional 15+ clinical trials and 4 preclinical research programs underway. Further, the Drink HRW technology is the only molecular hydrogen supplement on the market to obtain New Dietary Ingredient status after filing with the U.S. FDA.

For more information, please visit https://drinkhrw.com/

Related link: https://drinkhrw.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, NonProfit and Charities, Regional Events

COVID Variants Do Not Stop C. diff. Awareness Walks Worldwide

TEANECK, N.J. -- C Diff Foundation announced today that the 5th Annual Global C. diff. Awareness Walks will take place on-demand, on a livestream, and in-person at Sims Park, New Port Richey, FL, and Brown Street Park Complex, Spring city, PA, and Milton A. Votee, Teaneck, NJ. This year's annual events will take place on Saturday, September 25, 2021, from 9 a.m. - 12 p.m. EDT. Learn more at: https://www.cdiffwalks.com

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. During these unprecedented times the C Diff Foundation effectively adapts to overcome the many obstacles developing from this global virus and the variants of SARS-CoV-2 that have been emerging and circulating around the world throughout the COVID-19 pandemic.

C. diff. infections are one of the leading healthcare-associated infections facing local communities worldwide. According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C. diff., C. difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"C Diff Foundation volunteering members have a passion to improve the lives of patients, families, and caregivers who have been impacted by C. diff. infections worldwide," says Nancy C. Caralla, Founding President, Executive Director of the C Diff Foundation. "At the in-person C. diff. Awareness Walks, a safe distance will be maintained, and hand sanitizer will be available to ensure a safe outdoor event. 'Let's Walk' presents educational information shared by health care professionals, and C. diff. Survivors, through on-demand walks and livestream options located on the dedicated event website: https://cdiffwalks.com."

Thank you, Ferring Pharmaceuticals, for being the Global Sponsor of the 5th Annual Global C. diff. Awareness Walks. Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. For more information visit https://www.ferringusa.com.

We also extend our thanks to Seres Therapeutics, Inc. for being the Diamond Sponsor of the 5th Annual Global C. diff. Awareness Walks.

Seres Therapeutics, Inc. is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit https://www.serestherapeutics.com.

About C Diff Foundation:

C Diff Foundation, a 501(c)(3) nonprofit, is the leading patient and healthcare organization educating and advocating for C. difficile (Clostridioides difficile, C. diff., CDI, CDAD) prevention, treatments, clinical trials, diagnostics, support, and environmental safety worldwide. Their Mission continues to move forward and grow through research conducted by government, industry, and academia strengthening the advocacy on behalf of patients, families, caregivers, healthcare professionals, and researchers worldwide. For more information: https://cdifffoundation.org/

Follow C Diff Foundation:

Twitter @cdiffFoundation

#cdiffwalks2021 #cdiff2021

C Diff Foundation(tm) is a trademark of C Diff Foundation, established 2012 in the U.S.

MEDIA CONTACT:

Kathy Bischoff, Global Walk Committee

kathy@cdifffoundation.org

(727) 205-3922

MULTIMEDIA:

IMAGE link for media: https://www.Send2Press.com/300dpi/21-0920s2p-cdf-events-300dpi.jpg

Related link: https://cdifffoundation.org/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles

Pure Transplant Solutions, LLC Announces Research Collaboration with the Department of Surgery at the University of Cambridge

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a research collaboration with The University of Cambridge Abdominal Transplant Centre at Addenbrooke's Hospital, to develop new diagnostic strategies for DSA monitoring and characterization in transplantation.

The research is being led by Dr. Vasilis Kosmoliaptsis, Honorary Consultant Abdominal Transplant and HPB Surgeon, and Dr. Rico Buchli, Vice President Products and Services and Director of Research at PTS and its parent company, Pure Protein, LLC. The research project aims to investigate the relationship between alloantibody-HLA binding strength and the capacity of alloantibodies to mediate graft injury in solid organ transplantation, with the goal to develop and validate new HLA-antibody assays that will define the future thinking of antibody affinity in transplant rejection.

Dr. Kosmoliaptsis's group and collaborators have recently developed a novel immunoassay (microfluidic antibody affinity profiling) that enables quantification of antibody affinity and concentration directly in patient sera thus allowing clinical translation of this research for patient benefit. If successful, such data will potentially facilitate a new diagnostic tool to quantify alloantibody-mediated immunological risk that may enable improved access to transplantation, reduce the risk of humoral rejection, and improve transplant outcomes.

"Antibody affinity matters, and we believe that this work has the potential to transform clinical practice in transplantation," Dr. Kosmoliaptsis stated. "The provision of purified and naturally folded HLA reagents by PTS for use in our kinetics experiments provides an exciting opportunity to increase our understanding of the pathogenic potential of HLA-specific antibodies in the context of transplantation and to improve long-term transplant outcomes."

"This research will provide compelling new evidence supporting the role of DSA affinity assessment in risk stratification of donor-specific humoral responses. We foresee that this new insight into HLA antibody kinetics will provide new strategies and diagnostics that could help improve individual patient care and ultimately increase the lifespan of transplants," said Dr. Buchli.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aid in improving the design of vaccination and therapeutic targeting strategies.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.